Windward Bio Lists on Nasdaq, Shares Up 68% on Debut
PR Newswire•16/11/2026•08:28 ET
0
Key Highlights
- ➤Windward Bio priced IPO at $17.00, selling approximately 10.29 million shares
- ➤IPO raised $225 million gross proceeds, including Sanofi's $50 million private placement
- ➤Shares gained 68% on debut, giving Windward approximately $1.69 billion market capitalization
- ➤WIN378 advances in Phase 2/3 asthma and Phase 2 COPD trials
- ➤Top-line WIN378 asthma data expected first half 2027; Phase 3 data targeted first half 2029
Windward Bio Lists on Nasdaq, Shares Up 68% on Debut PR Newswire
Pivotal bioVenture Partners China-backed biotech built under the NewCo model on China-licensed assets debuts on Nasdaq less than two years after founding
Get started
Create a free account to read the full story.
